Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UnitedHealthcare

Division of UnitedHealth Group Co.

Latest From UnitedHealthcare

Biosimilar Uptake Gains Momentum In The US

Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress. 

Biosimilars Market Access

Payer, Provider Strategies To Encourage Biosimilar Uptake Gain Momentum

Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress. 

Biosimilars Reimbursement

Rybelsus, Other Treatment Improvements For Chronic Disease Have OptumRx’s Attention

UnitedHealthcare’s pharmacy benefit manager highlights potential cost pressures from upcoming novel or improved treatments for diabetes, wet AMD, HIV and migraine, as well as luspatercept for beta thalassemia, in its latest pipeline report.

Pricing Strategies Reimbursement

Amgen's US Biosimilar Launches Are Off To A Steady Start, With A Big Coverage Decision

United HealthCare agreed to cover Mvasi and Kanjinti in a preferred position. Amgen VP-oncology sales & marketing Susan Logan talked to Scrip about the company's first US biosimilar launches.

Biosimilars Launches
See All

Company Information

UsernamePublicRestriction

Register